

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number
WO 2005/051286 A3

- (51) International Patent Classification⁷: **A61K 31/52, B32B 27/32, 27/36, A61J 1/00**
- (21) International Application Number: **PCT/BR2004/000235**
- (22) International Filing Date:
25 November 2004 (25.11.2004)
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
PI0305339-3 28 November 2003 (28.11.2003) BR
Prov.000022040150576
23 November 2004 (23.11.2004) BR
- (71) Applicants (for all designated States except US): **HALEX ISTAR INDÚSTRIA FARMACÊUTICA LTDA.** [BR/BR]; BR 153, KM 03, Chácara Retiro, 74775-027 Goiânia (BR). **LABOGEN S/A QUÍMICA FINA E BIOTECNOLOGIA** [BR/BR]; Rua Hermínio de Mello, 311, Distrito Industrial, 13347-330 Indaiatuba (BR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **PERILLO, Heno** [BR/BR]; Rua L, 53, Apto. 101, Ed. Pitagueras Setor Oeste, 74120-050 Goiânia (BR). **CAMPOS NETO, José** [BR/BR]; Rua Hermínio de Mello, 311, Distrito Industrial, 13347-330 Indaiatuba (BR). **CRUCELLI, Márcio** [BR/BR]; Rua Hermínio de Mello, 311, Distrito Industrial, 13347-330 Indaiatuba (BR).
- (74) Agent: **LLC INFO CONNECTION LTDA.**; 5555 Dom Hélder Câmara Av., RM 312, Pílares, 20771-001 Rio de Janeiro - RJ (BR).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
9 September 2005
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **STABLE READY-FOR-USE INJECTABLE SOLUTION OF 9-((1,3-DIHYDROXYPROPAN-2-YLOXY) METHYL)-2-AMINE-1H-PURIN-6(9H)-ONE.**

(57) Abstract: The present invention describes a sterile, stable and ready-for-use injectable solution comprising 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one in glucose 5% aqueous solution or sodium chloride 0.9% aqueous solution. It also describes a closed system used for packing the solution, which consists of a flexible bag manufactured with a tri-laminated material. The present invention also describes a process for eliminating the residual alkalinity that is present in the 9-((1,3-dihydroxypropan-2-iloxy)methyl)-2-amino-1H-purin-6(9H)-one, so obtaining crystals that are free from alkaline residues and suitable for the direct preparation of the solution. The present invention relates to the medical and therapeutic areas, mainly for treating immunodepressed patients carrying viral infections.

WO 2005/051286 A3